The 15 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 105.00, with a high estimate of 140.00 and a low estimate of 47.00. The median estimate represents a +18.34% increase from the last price of 88.73.
The current consensus among 18 polled investment analysts is to Buy stock in CRISPR Therapeutics AG. This rating has held steady since October, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.17
Reporting Date Nov 04
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.